Compare Revolution Medicines Inc. Common Stock (RVMD) vs Toro Company (The) Common Stock (TTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revolution Medicines Inc. Common Stock vs Toro Company (The) Common Stock — how do they compare? Revolution Medicines Inc. Common Stock trades at $190 (market cap $41.53B), while Toro Company (The) Common Stock trades at $98.27 (market cap $9.30B). The key difference: Revolution Medicines Inc. Common Stock is far larger — about 4.5× Toro Company (The) Common Stock's market cap, and Toro Company (The) Common Stock pays a 1.59% dividend while Revolution Medicines Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revolution Medicines Inc. Common Stock for 2 Days and Toro Company (The) Common Stock for 0 Days on average.
| RVMD | TTC | |
|---|---|---|
Market Cap | $41.53B | $9.30B |
Volume | 2,462,910 | 420,909 |
Sector | Health | Industrials |
52-Week High | $221.15 | $101.76 |
52-Week Low | $49.56 | $67.99 |
Typical Hold Time | 2 Days | 0 Days |
Enterprise Value | $38.24B | $10.20B |
Dividend Yield | — | 1.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Revolution Medicines (RVMD) trades at $188.44, down 2.84% on the day, amid a bearish technical signal. The company reported no revenue in 2025, with a net loss of $1.13 billion, and has missed earnings expectations for three consecutive quarters. However, recent positive developments include the start of a Phase 3 trial for RASONQUE in pancreatic cancer and FDA Breakthrough Therapy Designation, fueling analyst optimism.
The outlook balances high-risk, high-reward potential. Strong analyst support (91.67% buy ratings) and a $253.35 consensus price target suggest significant upside, driven by the promising oncology pipeline. Key risks include substantial cash burn, lack of current revenue, and clinical trial execution uncertainties, making the stock suitable for investors comfortable with biotech volatility.
Toro Company (TTC) trades at $97.88, up 1.27% with strong technical momentum above its 50-day moving average. The company demonstrates solid fundamentals with consistent earnings beats, including Q2 2026 EPS of $1.33 beating expectations of $1.31, and raised full-year guidance. Revenue growth of 8.4% in Q3 2026 to $1.23 billion reflects robust demand across professional and residential segments, supported by infrastructure and automation initiatives under new CEO leadership.
Toro presents a balanced investment case with 36% analyst buy ratings and $117.50 price target suggesting 20% upside. However, execution risks from inflation, tariffs, and competitive pressures warrant caution. The stock's premium valuation (P/E 26.17) requires sustained earnings growth, making Q3 2026 results critical for validating current momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Revolution Medicines Inc. Common Stock
Revolution Medicines develops precision medicines for cancer. Its programs focus on targeting RAS-driven cancers and related signaling pathways.
Read more on RVMD →About Toro Company (The) Common Stock
The Toro Company designs, manufactures, and markets equipment for turf maintenance, snow and ice management, landscaping, construction, and irrigation. Its products serve golf courses, sports fields, and residential and commercial properties in more than 125 countries.
Read more on TTC →
